ABSTRACT
Introduction
Medulloblastoma is the predominant form of embryonal tumor, which is characterized by densely packed cells with high mitotic activity and an ability to spread throughout the central nervous system (1) . Forty percent of patients suffering from medulloblastoma were also found to be dealing with distant metastasis at diagnosis (2) , making it a real challenge to treat this malignancy. Current therapeutic approaches to medulloblastoma consist of surgery, radiation and nontargeted chemotherapy, although these strategies have led to significant loss of quality of life, due to cognitive or hormonal deficiencies; deaths have resulted from the effects of nonspecific, antimitotic agents on the developing brains of young medulloblastoma patients (3, 4) . Therefore, alternative therapeutic approaches are urgently needed in the clinic.
Given the rapid development of our understanding of the genome and transcriptome sequencing technologies, as well as the implementation of genomics consortiums such as ENCODE and FANTOM, the classic view of the transcriptome landscape and its mRNA-centric paradigm for transcript annotation has undergone a fundamental change (5, 6) . It is wellknown that the vast majority of the genome serves as the template for the transcription of noncoding RNAs. Among the noncoding RNAs, long noncoding RNAs (lncRNAs), which are a class of RNA stretching more than 200 nucleotides in length, have been widely investigated and identified as key regulators of various biological processes, including cell proliferation, differentiation, apoptosis, migration and invasion (7, 8) . Accumulating evidence has also shown the potential role of lncRNAs in numerous diseases, including cancers. Multiple lncRNAs have been functionally identified to exhibit procancerous capabilities, such as metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) (9) and HOX antisense intergenic RNA (HO-TAIR) (10) . All of these studies have suggested that lncRNAs play a critical role in human tumorigenesis.
Among all of the lncRNAs, colon cancer-associated transcript-1 (CCAT1) is unique, with many studies having shown that it is strongly associated with various cancers. CCAT1 is an lncRNA comprising 2,628 nucleotides, and it maps to chromosome band 8q24.21. CCAT1 was initially reported to be upregulated in colon cancer in 2012 (11) , and has since been a rising star of oncogenic lncRNAs (12) . The expression of CCAT1 was increased in a variety of cancers, including hepatocellular carcinoma (13) , breast cancer (14) , pancreatic cancer (15) and squamous cell carcinoma (16, 17) . Functionally speaking, CCAT1 has been shown to promote hepatocellular carcinoma cell proliferation and invasion (18) . In fact, CCAT1 was found to play critical pro-oncogenic roles in human tumorigenesis, while findings also showed that CCAT1 promoted glioma cell proliferation (19) , regulated gastric cancer migration (20) and promoted chemoresistance in lung adenocarcinoma (21) . As such, it is clear that CCAT1 is a pivotal oncogenic lncRNA in human cancers (8, 12) . However, the role of CCAT1 in human medulloblastoma remains to be elucidated.
The present study aimed to examine the roles of CCAT1 in medulloblastoma in vitro and in vivo. The expression profile of CCAT1 in clinical medulloblastoma tissues and in a series of medulloblastoma cell lines was initially assessed. The effects of CCAT1 knockdown on medulloblastoma cell lines were then explored. Our results showed that CCAT1 was a critical mediator of cell proliferation, migration and invasion in medulloblastoma. The biological activity of CCAT1 was accompanied by the MAPK pathway. Our conclusion might well pave the way for novel insights into the clinical treatments of medulloblastoma.
Material and methods

Human tissues and ethical statements
A total of 20 cases involving the diagnosis of medulloblastoma were obtained. For each case, the cancerous tissues, as well as their adjacent noncancerous tissues, were collected. All patients gave their full consent to participate in our study, and a written consent form was obtained from each pediatric patients. The protocol to use human tissues was in compliance with the official policies and approved by the ethics committee of Jining No. 1 People's Hospital.
Cell lines and cell culture
Five human medulloblastoma cell lines, namely Daoy, D283, D425, D341 and D458, were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). All cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco) and supplied with 10% fetal bovin e serum (FBS; Gibco). The cells were cultured in a humidified incubator containing 95% CO 2 . The culture medium was refreshed every 2 days.
Total RNA extraction and quantitative real-time polymerase chain reaction All of the RNAs from each sample were isolated using Trizol Reagent (Thermo Fisher Scientific) based on the manufacturer's instructions. After the RNA quality check, the RNA concentration was determined under a wavelength of 260 nm with Nanodrop 2000. The RNA was then reverse transcribed into cDNAs using the PrimeScript RT Master Mix Perfect Real Time (TaKaRa). The transcription of CCAT1 was measured by quantitative polymerase chain reaction (qPCR) using cDNAs as the template and the SYBR Premix Ex Taq Kit (TaKaRa, Japan) in an ABI PRISM 7500 Real-Time System. The primers used are listed below, and β-actin was included as the internal control. Each experiment was performed in triplicate at least 3 times. CCAT1, forward: 5'-CATTGGGAAAGGTGCCGAGA-3', reverse: 5'-ACGCTTAGCCATACAGAGCC-3'; β-actin, forward: 5'-GACATGGAGAAGATCTGG CA -3', reverse: 5'-GGTCTTTACG-GATGTCAACG-3'.
Western blot analysis
All proteins were extracted using a lysis buffer to generate the whole protein lysate. After protein quantification, an equal amount of 40 μg protein was separated by means of a 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene fluoride (PVDF) membrane. The membrane was blocked in Tris-buffered saline (TBS) with skim milk and then incubated with primary antibodies overnight at 4°C. A corresponding secondary antibody, which recognizes the primary antibody, was then added, and the immunoreactivity was determined using enhanced chemoluminescent autoradiography ( Thermo Scientific). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was synchronously developed for loading control. Each experiment was repeated at least 3 times.
Cell cycle analysis
To analyze the cell cycle, the serum was deprived for 24 hours to synchronize said cell cycle. The cells with distinct treatments were then synchronously cultured with DMEM and 5% serum for another 24 hours. Daoy and D283 cells were then fixed with 80% cold ethanol and incubated with 0.5% Triton X-100 solution containing 1 mg⁄mL RNase A at 37°C for 30 minutes. Propidium iodide solution (Sigma) was then added to each well with a final concentration of 50 μg⁄mL. Cells were further incubated for 60 minutes in the dark. Following this, the cell cycle progression was analyzed using a FACS (Becton Dickinson, Franklin Lakes, NJ, USA). Data were processed using WinMDI29 software (Becton Dickinson).
Cell viability assay
Cells with and without CCAT1 knockdown were subjected to viability determination using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Sigma). Briefly, Daoy and D283 cells (scramble and short hairpin RNA [shRNA] groups) were seeded into 96-well plates at an initial 5 × 10 4 cells/well. Cell numbers were then monitored for 5 consecutive days. For each monitored time, 10 μL of MTT reagent was added to each well. The cells were then incubated at 37˚C for another 2 hours. The absorbance of each group of cells was read at 490 nm using a microplate ELISA reader (Bio-Rad Laboratories).
Colony formation assay
A plate colony formation assay was utilized to evaluate the effects of CCAT1 knockdown on anchorage-dependent cell growth. In brief, Daoy and D283 cells with and without CCAT1 knockdown (scramble group and shRNA group, respectively) were seeded at a density of 120 cells⁄well in 6-well plates. The cells were then allowed to grow freely. After 10 days, the cells were washed with phosphate-buffered solution (PBS) twice and stained with crystal violet. A clone was defined as a colony with over 50 cells. The number of visible colonies was manually counted for each group.
Wound-healing and Transwell assays
The wound-healing assay and Transwell assay (Corning) were employed to evaluate the effects of CCAT1 knockdown on cell metastasis. For the wound-healing assay, cells were plated on 6-well plates to form a confluent monolayer. Artificial wounds were made vertically with sterile pipette tips, and the wound recovery was observed every 6 hours. The rate of wound recovery was then calculated after 24 hours of monitoring. For the Transwell assays, Boyden chambers (tissue culture-treated, 6.5-mm diameter, 8-μm pores; Transwell; Costar) containing polycarbonate membrane were used. For the Transwell migration assay, 100 μL of 1 × 106 cells in serum-free medium was seeded to the upper chamber, and 600 μL of DMEM with 10% FBS was added to the lower chamber. Cells were then incubated for 12 hours at 37°C. Migrated cells on the undersurface of the membrane were fixed and stained with crystal violet for 10 minutes at room temperature. For the invasion assay, the protocols were similar to those for the Transwell migration assays, except that an aliquot of Matrigel (50 μL) (BD Biosciences) was applied to the upper surface to mimic the basement membrane. After staining, 5 random regions were photographed, and the cells were counted to calculate the average number of migrated cells per group.
A mouse model of xenograft medulloblastoma
A total of 20 athymic nude mice aged 6 weeks were randomly assigned as the control group and the shRNA group (n = 5/group per cell line). A xenograft model of medulloblastoma was established by injecting Daoy cells or D283 cells (2 × 10 6 ) into the right flank of each mouse. For the shRNA group, the CCAT1-depleted cells were used for injection, while the control group was exposed to the scramble shRNAtreated cells. The diameters of the neoplasia in each group of mice were periodically measured, and the tumor volume (TV) was calculated as TV = L × W 2 /2, where L is the length and W the width.
Four weeks after inoculation, all mice were sacrificed, and tumors were excised. The excised tumors were weighed and photographed. All efforts were made to minimize suffering. Protocols for animal experiments were approved by the ethics committee of Jining No. 1 People's Hospital.
Statistical analysis
All data are expressed as means ± standard deviation (SD). Student's t-test was used to evaluate the difference between groups. A p value <0.05 was considered statistically significant.
Results
lncRNA CCAT1 is highly expressed in medulloblastoma tissues and differentially expressed in medulloblastoma cell lines
To assess the expression profile of lncRNA CCAT1 in medulloblastoma, we initially measured the relative transcription level of CCAT1 in 20 cases of clinical medulloblastoma patients. It was found that the transcription of CCAT1 increased dramatically in the cancerous tissues when compared with the paired noncancerous tissues. In all 20 cases, the transcription of CCAT1 in cancerous tissues was 2.5-10 times higher than that in noncancerous tissues (Fig. 1A) . In the series of medulloblastoma cell lines, it was found that Daoy cells exhibited the highest transcription of CCAT1, followed by D283 cells, D425 cells and D341 cells. D458 cells had the lowest transcription of CCAT1 (Fig. 1B) . The high expression of CCAT1 in Daoy cells and D283 cells made these 2 cell lines optimal for subsequent functional assays. These data suggest that CCAT1 is highly expressed in medulloblastoma tissues and differentially expressed in the medulloblastoma cell lines.
Depletion of CCAT1 inhibits cell proliferation in medulloblastoma cells
Following this, we employed shRNA to deplete the expression of CCAT1 in Daoy cells and in D283 cells. Both the transfection of specific shRNA against CCAT1 (shRNA group) and the scrambling of shRNA (scramble group) into both cell lines were highly efficient, as observed in Figure 2A . Following transfection of specific shRNA, the transcription level of CCAT1 decreased by 80% in Daoy cells (Fig. 2B) and by up to 90% in D283 cells (Fig. 2C) , thus validating the successful establishment of CCAT1-depleted Daoy cells and CCAT1-depleted-D283 cells.
Subsequently, both control and CCAT1-depleted cells were subject to cell viability detection and colony formation assay. In the cell viability assay, it was observed that CCAT1-depleted cells began to exhibit lower proliferative rates after 2 days. By the fifth day following CCAT1 knockdown, the proliferative rates had decreased by up to 51.2% in Daoy cells (Fig. 3A) and approximately 37.5% in D283 cells (Fig. 3B) . Colony formation was also visually inhibited by shRNA against CCAT1 in both cell lines (Fig. 3C) . In fact, only 10 colonies were formed in CCAT1-depleted Daoy cells, which was in stark contrast to the 60 in the scramble group of Daoy cells. Similarly, only an average of 18 colonies were counted in CCAT1-depleted D283 cells, which was again nothing close to the almost 55 colonies in the scramble group of D283 cells (Fig. 3D) . These data suggest that knockdown of CCAT1 inhibits tumor growth in medulloblastoma cells.
Depletion of CCAT1 disrupts cell cycle progression in medulloblastoma cells
Further, the cell cycle was analyzed for both cell lines, with the findings revealing that the cell proportions in each phase of the cell cycle had changed between the scramble and the shR-NA group of cells (Fig. 4A and B) . In the Daoy cells, when CCAT1 was depleted, cells were more accumulated in the S phase and G2/M phase (Fig. 4C) . In the D283 cells, knockdown of CCAT1 caused increases of cell proportions in the S phase and G2/M phase. The cell proportion in the G0/G1 phase was concordantly decreased (Fig. 4D) . The consistent observations for Daoy and D283 cells strongly suggested that depletion of CCAT1 arrests cell cycle progression during the S phase.
Depletion of CCAT1 inhibits tumor growth in xenotransplanted mice
In the xenografted model of human medulloblastoma, it was observed that knockdown of CCAT1 in Daoy cells caused a significant decrease in subcutaneous tumor volume after 3 weeks (Fig. 5A) . The excised neoplasia was visually smaller in size in the shRNA group (Fig. 5B) and had a significantly lower weight and mass in the shRNA group (Fig. 5C) . Likewise, following knockdown of CCAT1 in D283 cells, the average tumor volume decreased by approximately 60% by the fourth week (Fig. 5D) . The tumors were visually smaller (Fig.  5E ) and weighed less in the shRNA group than in the scramble group (Fig. 5F ). These in vivo observations suggested that CCAT1 is a pro-oncogenic factor in medulloblastoma.
Depletion of CCAT1 inhibits cell metastasis in medulloblastoma cells
The effects of CCAT1 knockdown on cell migration and invasion were then assessed. In the wound-healing assay, it was observed that, with regard to the CCAT1-depleted cells, the recovery of the scratched wound was hindered, whereas with the control cells, wound recovery was all but complete after 24 hours (Fig. 6A) . In fact, the wound only recovered 45% in the CCAT1-depleted Daoy cells, which equated to a decrease of 39.2% in cell migration capacity after 24 hours. Moreover, the wound only recovered 38% after 24 hours in the CCAT1-depleted D283 cells, which was in contrast to the 85% in the scramble D283 cells (Fig. 6B) . In the Transwell assay, both cell migration and invasion capacities were inhibited by knockdown of CCAT1 (Fig. 6C) . After counting the transmigrated cells, it was clear that only 52 of the CCAT1-depleted Daoy cells had migrated to the lower surface, whereas an average of 150 control cells were seen on the lower surface. Only 40 CCAT1-depleted D283 cells transmigrated, which contrasted significantly with the 125 cells in the scramble control group (Fig. 6D) . Likewise, there was an approximate 70% decrease of invaded cells in Daoy cells and a 52.9% decrease in D283 cells after knockdown of CCAT1 in each cell line (Fig. 6E) . The in vitro data suggested that knockdown of CCAT1 inhibits cell metastasis in medulloblastoma cells.
Depletion of CCAT1 inactivates the MAPK pathway
Following this, it was observed that, after knockdown of CCAT1 in Daoy and D283 cells, the phosphorylated levels of MAPK (p-MAPK), MEK (p-MEK) and ERK (p-ERK) decreased accordingly, with their total levels unchanged. In addition, cell cycle-related protein cyclin A and CDK2 also decreased in the shRNA group (Fig. 7) . This suggested that depletion of CCAT1 inactivates the MAPK pathway.
Discussion
Medulloblastoma is clinically characterized by high invasiveness and metastasis through cerebrospinal fluid (CSF). Approximately 40% of patients may present with distant metastasis when being diagnosed with medulloblastoma (2). Though patients suffering from medulloblastoma have a relatively good long-term survival rate, they are still plagued by complications due at least in part to the intensive therapies given to ensure the eradication of the tumor (22) . Over recent decades, an increasing incidence rate has been observed for medulloblastoma, especially in infants and young children (23) . This high incidence rate has mandated the development of novel treatments and drugs.
LncRNA CCAT1 is a novel lncRNA that was initially identified in colon cancer in 2012. Ever since its identification, accumulating evidence has shown that CCAT1 plays critical oncogenic roles in various cancers. However, the details regarding these roles of CCAT1 in medulloblastoma remain unidentified. In the present study, we initially found that the expression of CCAT1 was significantly increased in clinical medulloblastoma tissues. The aberrant expression of CCAT1 was consistent with its manner in other cancer types (7, 13) , thus suggesting the ubiquitous up-regulation of CCAT1 in human tumorigenesis. More importantly, after knockdown of CCAT1 in medulloblastoma Daoy cells and D283 cells, it was found that cell proliferation was inhibited in vivo and in vitro. Cell cycle arrest is a hallmark of tumor growth inhibition (24) . We found that the depletion of CCAT1 caused significant cell cycle arrest in the S phase, thus clearly showing that CCAT1 could promote tumor growth in medulloblastoma. Furthermore, it was interesting to observe that cell migration and invasion capacities were also inhibited by CCAT1 depletion. Previous studies have reported that CCAT1 regulated cancer cell migration and invasion (17, 18, 20) . When combining these results with our findings, it could be concluded that CCAT1 has a wide oncogenic role in human tumorigenesis. The widespectrum cancer-promotion effect suggest that therapeutic drugs against CCAT1 may have the potential to treat a wide range of cancers.
Importantly, the current study also found that knockdown of CCAT1 was associated with inactivation of the MAPK pathway. The MAPK pathway is activated by cascade phosphorylation. Indeed, many studies have shown that activation of the MAPK pathway is associated with tumorigenesis. In hepatocellular carcinoma, the MAPK pathway is constitutively activated (25) . ERK is highly phosphorylated in tumor tissues and has been shown to be significantly correlated with hepatocellular carcinoma tumor size (26) . ERK activation has been associated with aggressive tumor behavior and can serve as an independent prognostic marker for decreased overall survival (27) . The association of CCAT1 with the MAPK pathway suggested that CCAT1 plays its oncogenic roles by regulating the MAPK pathway. Meanwhile, unlike previous studies, which showed that CCAT1 mainly worked as a microRNA sponge or a competing endogenous RNA (7, 19, 20) , the present study showed that the MAPK pathway underlined CCAT1 biological activity. This finding is unique and shows that CCAT1 may have broad mechanistic activities in human tumorigenesis. The identification of these mechanisms may be valuable for our understanding of the functional roles of CCAT1.
In all, the present study showed that CCAT1 was highly expressed in medulloblastoma tissues. Knockdown of CCAT1 significantly inhibited cell proliferation, migration and invasion. Moreover, the MAPK pathway may be involved in CCAT1-regulated medulloblastoma progression. Our results validate the oncogenic role of CCAT1 in human cancers, and suggest that therapeutic targets against CCAT1 may be promising as a treatment for medulloblastoma in clinics.
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